IBDEI10M ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16511,1,4,0)
 ;;=4^C82.39
 ;;^UTILITY(U,$J,358.3,16511,2)
 ;;=^5001500
 ;;^UTILITY(U,$J,358.3,16512,0)
 ;;=C82.30^^61^775^76
 ;;^UTILITY(U,$J,358.3,16512,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16512,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIa,Unspec Site
 ;;^UTILITY(U,$J,358.3,16512,1,4,0)
 ;;=4^C82.30
 ;;^UTILITY(U,$J,358.3,16512,2)
 ;;=^5001491
 ;;^UTILITY(U,$J,358.3,16513,0)
 ;;=C82.49^^61^775^77
 ;;^UTILITY(U,$J,358.3,16513,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16513,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,16513,1,4,0)
 ;;=4^C82.49
 ;;^UTILITY(U,$J,358.3,16513,2)
 ;;=^5001510
 ;;^UTILITY(U,$J,358.3,16514,0)
 ;;=C82.40^^61^775^78
 ;;^UTILITY(U,$J,358.3,16514,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16514,1,3,0)
 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
 ;;^UTILITY(U,$J,358.3,16514,1,4,0)
 ;;=4^C82.40
 ;;^UTILITY(U,$J,358.3,16514,2)
 ;;=^5001501
 ;;^UTILITY(U,$J,358.3,16515,0)
 ;;=C82.99^^61^775^79
 ;;^UTILITY(U,$J,358.3,16515,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16515,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,16515,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,16515,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,16516,0)
 ;;=C82.90^^61^775^80
 ;;^UTILITY(U,$J,358.3,16516,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16516,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,16516,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,16516,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,16517,0)
 ;;=R59.1^^61^775^65
 ;;^UTILITY(U,$J,358.3,16517,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16517,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,16517,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,16517,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,16518,0)
 ;;=C91.40^^61^775^84
 ;;^UTILITY(U,$J,358.3,16518,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16518,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,16518,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,16518,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,16519,0)
 ;;=C91.42^^61^775^82
 ;;^UTILITY(U,$J,358.3,16519,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16519,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,16519,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,16519,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,16520,0)
 ;;=C91.41^^61^775^83
 ;;^UTILITY(U,$J,358.3,16520,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16520,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,16520,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,16520,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,16521,0)
 ;;=D57.01^^61^775^85
 ;;^UTILITY(U,$J,358.3,16521,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16521,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,16521,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,16521,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,16522,0)
 ;;=D57.00^^61^775^86
 ;;^UTILITY(U,$J,358.3,16522,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16522,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,16522,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,16522,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,16523,0)
 ;;=D57.02^^61^775^87
 ;;^UTILITY(U,$J,358.3,16523,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16523,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
